← Back to headlines
J&J's Imaavy shows long-term control in myasthenia gravis
Johnson & Johnson's drug Imaavy has demonstrated long-term disease control in patients suffering from myasthenia gravis, offering a potential new treatment option.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
